Observations with Bazoton® in the management of prostatic hyperplasia

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Thirty patients with prostatic hyperplasia stages I and II were administered Bazoton® capsules (extract of Radix Urticae) for an average period of 3.5 months. Residual urine, mean and maximal flow were measured before and after treatmet. A significant decrease in the volume of residual urine was found. Increase in mean urinary flow was also significant. Maximal urinary flow increased in 50% of the cases. A marked subjective relief was reported by the patients. Bazoton is regarded as suitable for the conservative treatment of prostatic hyperplasia stages I and II.

Original languageEnglish
Pages (from-to)293-297
Number of pages5
JournalInternational Urology and Nephrology
Volume19
Issue number3
DOIs
Publication statusPublished - Sep 1987

Fingerprint

Prostatic Hyperplasia
Urine
Residual Volume
Capsules
Bazoton
Conservative Treatment

ASJC Scopus subject areas

  • Urology
  • Nephrology
  • Geriatrics and Gerontology

Cite this

Observations with Bazoton® in the management of prostatic hyperplasia. / Romics, I.

In: International Urology and Nephrology, Vol. 19, No. 3, 09.1987, p. 293-297.

Research output: Contribution to journalArticle

@article{efeb5f45780147759bfdfaa2ca04ac5c,
title = "Observations with Bazoton{\circledR} in the management of prostatic hyperplasia",
abstract = "Thirty patients with prostatic hyperplasia stages I and II were administered Bazoton{\circledR} capsules (extract of Radix Urticae) for an average period of 3.5 months. Residual urine, mean and maximal flow were measured before and after treatmet. A significant decrease in the volume of residual urine was found. Increase in mean urinary flow was also significant. Maximal urinary flow increased in 50{\%} of the cases. A marked subjective relief was reported by the patients. Bazoton is regarded as suitable for the conservative treatment of prostatic hyperplasia stages I and II.",
author = "I. Romics",
year = "1987",
month = "9",
doi = "10.1007/BF02549866",
language = "English",
volume = "19",
pages = "293--297",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Observations with Bazoton® in the management of prostatic hyperplasia

AU - Romics, I.

PY - 1987/9

Y1 - 1987/9

N2 - Thirty patients with prostatic hyperplasia stages I and II were administered Bazoton® capsules (extract of Radix Urticae) for an average period of 3.5 months. Residual urine, mean and maximal flow were measured before and after treatmet. A significant decrease in the volume of residual urine was found. Increase in mean urinary flow was also significant. Maximal urinary flow increased in 50% of the cases. A marked subjective relief was reported by the patients. Bazoton is regarded as suitable for the conservative treatment of prostatic hyperplasia stages I and II.

AB - Thirty patients with prostatic hyperplasia stages I and II were administered Bazoton® capsules (extract of Radix Urticae) for an average period of 3.5 months. Residual urine, mean and maximal flow were measured before and after treatmet. A significant decrease in the volume of residual urine was found. Increase in mean urinary flow was also significant. Maximal urinary flow increased in 50% of the cases. A marked subjective relief was reported by the patients. Bazoton is regarded as suitable for the conservative treatment of prostatic hyperplasia stages I and II.

UR - http://www.scopus.com/inward/record.url?scp=0023161986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023161986&partnerID=8YFLogxK

U2 - 10.1007/BF02549866

DO - 10.1007/BF02549866

M3 - Article

VL - 19

SP - 293

EP - 297

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 3

ER -